H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod

Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts.

Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the most promising stocks.

On February 23, 2026, H.C. Wainwright increased the price target for ARMP from $9.00 to $15.00 and kept a Buy rating on the shares. The modification comes after the FDA designated AP-SA02 as a Qualified Infectious Disease Product, providing extra regulatory support as the business gets ready for its Phase 3 superiority research, which is set for the second half of 2026.

Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) declared on February 23 that its intravenous Staphylococcus aureus multi-phage candidate, AP-SA02, has been given Qualified Infectious Disease Product (QIDP) classification by the U.S. FDA. Its usage as an adjuvant treatment for complex bacteremia brought on by both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) S. aureus is covered by the designation. In the second half of 2026, the company plans to place AP-SA02 into a Phase 3 superiority trial for complex bloodstream infections caused by S. aureus.

Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is a clinical-stage biotech company developing precision bacteriophage-based therapies to treat antibiotic-resistant and hard-to-treat bacterial infections, advancing a pipeline of pathogen-specific phage candidates from discovery through clinical trials.

READ NEXT: 14 Best GARP Stocks to Buy According to Analysts and 14 Best Affordable Dividend Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.